[
  {
    "ts": null,
    "headline": "CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?",
    "summary": "CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.",
    "url": "https://finnhub.io/api/news?id=037d43326e3bed3ec66d8a1cb6291700953c22ac6a62b7a0bce6d97853b79f50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756385280,
      "headline": "CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?",
      "id": 136558044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.",
      "url": "https://finnhub.io/api/news?id=037d43326e3bed3ec66d8a1cb6291700953c22ac6a62b7a0bce6d97853b79f50"
    }
  }
]